Patent 9192621 was granted and assigned to Idenix Pharmaceuticals on November, 2015 by the United States Patent and Trademark Office.
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: